Genes encoding eight different KYNase enzymes of bacterial or mammalian origin were synthesized as Integrated DNA Technologies (IDT) gblocks using E. coli-optimized codons and an N-terminal 6× histidine affinity tag. Full-length genes encoding KYNase from H. sapiens (Hs-KYNase), Mus musculus (Mm-KYNase), M. paludis (Mp-KYNase), Cesiribacter andamanesis (Ca-KYNase), Fulvivirga imtechensis (Fi-KYNase), Cyclobacterium marinum (Cm-KYNase), Chlamydophila pecorum (Cp-KYNase), Acinetobacter Baumannii (Ab-KYNase) and P. fluorescens (Pf-KYNase) were inserted into a pet28a vector backbone ( Supplementary Table 1 ).
Increased tryptophan (Trp) catabolism in the tumor microenvironment (TME) can mediate immune suppression by upregulation of interferon (IFN)-g-inducible indoleamine 2,3-dioxygenase (IDO1) and/or ectopic expression of the predominantly liver-restricted enzyme tryptophan 2,3dioxygenase (TDO) [1] [2] [3] [4] [5] . Whether these effects are due to Trp depletion in the TME or mediated by the accumulation of the IDO1 and/or TDO (hereafter referred to as IDO1/TDO) product kynurenine (Kyn) remains controversial [5] [6] [7] [8] [9] [10] [11] [12] [13] . Here we show that administration of a pharmacologically optimized enzyme (PEGylated kynureninase; hereafter referred to as PEG-KYNase) that degrades Kyn into immunologically inert, nontoxic and readily cleared metabolites inhibits tumor growth. Enzyme treatment was associated with a marked increase in the tumor infiltration and proliferation of polyfunctional CD8 + lymphocytes. We show that PEG-KYNase administration had substantial therapeutic effects when combined with approved checkpoint inhibitors or with a cancer vaccine for the treatment of large B16-F10 melanoma, 4T1 breast carcinoma or CT26 colon carcinoma tumors. PEG-KYNase mediated prolonged depletion of Kyn in the TME and reversed the modulatory effects of IDO1/TDO upregulation in the TME.
Upregulation of Trp catabolism by IDO1/TDO represents one of the most studied and clinically validated pathways for immune suppression in tumors. These enzymes catalyze the oxidation of Trp to N-formyl l-kynurenine, which is rapidly converted by formamidases to Kyn. Elevated concentrations of Kyn and higher plasma Kyn/Trp ratios are frequently observed in patients with advanced-stage cancers and correlate with poor prognoses 8 . In addition to IDO1/TDO, Kyn can also be generated by the IDO2 isozyme; however, the role of IDO2 in cancer remains uncertain 9 . IDO1/TDO expression in the TME has been linked to the induction of numerous tolerogenic immune phenotypes, including the suppression of effector T cell activation, enhanced infiltration of myeloid-derived suppressor cells (MDSCs), B cell dysfunction and promotion of tumor angiogenesis 3 . IDO1 is upregulated in numerous malignancies in response to local inflammatory responses that arise from CD8 + T cell infiltration and from cross-talk with other immunosuppressive pathways 10, 11 . IDO1 expression has been shown to mediate resistance to cancer immunotherapy using CTLA4-specific and PD-1-specific antibodies and to inhibit chimeric antigen receptor (CAR)-T cell function in mouse models [12] [13] [14] . Furthermore, Kyn synthesis has also been reported to promote tumorigenesis in a manner independent of immunological effects, by activating β-catenin and the Akt-PI3K signaling pathway 15 . Small-molecule inhibitors of IDO1 are currently being evaluated in several clinical trials.
Mechanistically, early studies suggested that the immunosuppressive effect of Trp catabolism on T cells is a consequence of the reduction in the local concentration of Trp and the ensuing induction of general starvation responses through activation of the general control nonderepressible 2 kinase (GCN2) and/or suppression of the mechanistic target of rapamycin (mTOR) pathways 3 (Fig. 1a) . Elevated Trp catabolism also results in increased concentration of Kyn locally within the TME and systemically, when tumor burden is high. Kyn has been shown to be an aryl hydrocarbon receptor (AHR) ligand 16, 17 , whose activation and nuclear translocation induces a number of immunosuppressive phenotypes in T cells, including reprogramming of T helper 17 (T H 17) cells into regulatory T (T reg ) cells 16 . Furthermore, a recent report revealed that in addition to its direct effect on AHR, in vitro Kyn is slowly converted non-enzymatically to byproducts that serve as high-affinity reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme (subnanomolar) AHR agonists 18 . Downstream metabolites of the Trp catabolism and Kyn pathway, notably 3′-hydroxy-kynurenine (3′OH-Kyn) and 3′-hydroxy-anthranilic acid (3′OH-AA), are also AHR ligands; however, their concentration, at least in the serum of healthy humans, is 10-to 50-fold lower than that of Kyn 19 . The relative significance of Trp starvation responses versus Kyn accumulation in the TME as the driver for immunosuppression has been debated for almost 20 years. Although the view that localized Trp starvation is primarily responsible for the impaired T cell function in tumors remains prevalent, quantitative arguments and recent experimental evidence have begun casting doubts on this hypothesis [4] [5] [6] [7] .
Eliminating the extracellular pool of Kyn in a manner that does not affect the consumption of Trp by IDO1/TDO could help to unequivocally assess whether immunosuppression is driven primarily by Kyn accumulation in the TME or by Trp-starvation-induced mechanisms. We hypothesized that such selective removal of the extracellular Kyn pool could be accomplished through the systemic administration of an appropriate, pharmacologically optimized enzyme capable of degrading Kyn into nontoxic and immunologically inert metabolites ( Fig. 1a) . From a therapeutic standpoint, enzyme treatment could offer several important advantages relative to the small-molecule IDO1 inhibitors currently being evaluated clinically, including the ability to treat not only cancers in which IDO1 is upregulated but also tumors expressing TDO 1 , or both, along with other pharmacologically favorable features, as discussed below.
Of the three enzymes that use Kyn as a substrate-namely kynurenine monooxygenase, kynurenine aminotransferase and KYNaseonly the latter has biochemical and pharmacological properties (including cofactor requirements, ability to function in the relatively high redox environment of serum and interstitial fluid, biophysical stability and enzyme products that are unlikely to lead to adverse neurophysiological or immunological effects) to be a candidate for in vivo administration ( Supplementary Fig. 1 ) 20, 21 . The Homo sapiens KYNase catalyzes the degradation of Kyn with slow kinetics, and it has a strong preference for 3′OH-Kyn, the product of kynurenine monooxygenase (k cat /K M of 1.0 × 10 2 M −1 s −1 and 3.7 × 10 4 M −1 s −1 for Kyn and 3′OH-Kyn, respectively; Supplementary Table 1 ). Other eukaryotic KYNases also preferentially degrade 3′OH-Kyn with similar kinetics ( Supplementary Table 1 ) 22 . In initial experiments we expressed H. sapiens KYNase in Escherichia coli, purified it to near homogeneity (>95%) with low endotoxin content and then conjugated it to a 5 kDa polyethylene glycol N-hydroxysuccinimide (PEG-NHS) ester for prolonged systemic retention 23 . PEGylation did not impair the catalytic activity of the enzyme. However, peritumoral administration of the PEGylated H. sapiens KYNase to mice bearing established B16-F10 tumors had no effect on tumor growth or mean survival (data not shown). We reasoned that the lack of efficacy of the H. sapiens KYNase was a consequence of its poor kinetics with Kyn as a substrate. To address this problem, we expressed and characterized several prokaryotic KYNases that bioinformatically were predicted to have preferential activity for Kyn relative to that for 3′OH-Kyn (Supplementary Table 1 ). The Psuedomonas fluorescens and Mucilaginibacter paludis enzymes, which have k cat /K M values 760× and 570× greater than that of the human enzyme, respectively, were expressed, purified to near homogeneity and PEGylated as described above (Supplementary Fig. 2) . In contrast to the H. sapiens KYNase, administration of either of the highly catalytically active P. fluorescens or M. paludis enzymes resulted in strong antitumor effects in multiple mouse tumor models, as discussed below.
The addition of bacterial PEG-KYNases completely reversed Kyninduced cell death of activated mouse T cells in vitro ( Supplementary   Fig. 3 ). Previous studies have shown similar effects of Kyn on activated human T cells 24 . For in vivo experiments, mice were treated with either active P. fluorescens PEG-KYNase or the heat-deactivated enzyme as a control. Heat-deactivated, PEGylated protein, rather than mutant inactive enzyme was used as a control to properly account for the effects of protein batch-to-batch variation and for the presence of trace impurities. Dose-finding studies established that maximal efficacy was observed when the enzyme was administered peritumorally at 20 mg per kg body weight (mg/kg) ( Supplementary Fig. 4 ). Pharmacokinetic analysis revealed that PEG-KYNase was maintained at >10 µg/ml for at least 70 h after administration ( Supplementary  Fig. 5 ). As shown in Figure 1b , administration of active enzyme in mice bearing palpable syngeneic CT26 colon carcinoma tumors (day 4), which express IDO1, led to an ~45% improvement in mean survival time (23 d versus 33 d) relative to mice that received vehicle alone or the deactivated enzyme. Of note, ~15% of the mice had complete, durable responses that were accompanied by long-lasting and tumor-specific immunity, as demonstrated in re-challenge experiments ( Supplementary Fig. 6a ). We further observed that the effect of PEG-KYNase on mice bearing CT26 tumors was statistically indistinguishable from a group that received antibodies to programmed cell death 1 (PDCD1; also known as PD-1) ( Supplementary Fig. 7 ).
Next we evaluated the effect of PEG-KYNase administration on large tumors (>100 mm 3 , day 10) in the extensively studied B16-F10 mouse model of melanoma. B16-F10 cells do not express IDO1, however tumor growth potently induces the upregulation of IDO1 in the TME 5, 10 . As a monotherapy, administration of PEG-KYNase resulted in statistically significant (P < 0.0001) hindrance of tumor growth and increased mean survival relative to that in the control group (Fig. 1c) . Time-course liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) metabolomics analysis showed that within 8 h following enzyme administration, the serum concentration of Kyn was reduced by over 100-fold, to below the limit of detection (<1 pg/µl; Fig. 1d and Supplementary Table 2 ), and it remained undetectable for at least 48 h. The Kyn concentration in tumor samples was markedly elevated (~4×) relative to that in the serum, as expected given the upregulation of IDO1 in the TME in the B16-F10 model ( Fig. 1d) . Following PEG-KYNase administration, the tumor levels of Kyn were substantially reduced, to <5% of the values observed in mice that were treated with the deactivated enzyme. Consistent with the hypothesis presented above, Trp levels in B16-F10 tumors were comparable to those in the serum 19 and were unaffected by treatment with enzyme ( Fig. 1d) . The concentration of anthranilic acid, the product of enzymatic degradation of Kyn, was increased in the serum and transiently in the tumor samples ( Fig. 1d) . Treatment with PEG-KYNase did not affect the tumor levels of downstream metabolites of the Kyn pathway that are known AHR ligands, namely 3′OH-Kyn, 3′OH-AA and quinolinic acid (Supplementary Fig. 8 ). The concentration of these metabolites remained within or below the physiological range for humans 19 .
The effect of PEG-KYNase on the growth of B16-F10 tumors was completely abolished in Ido1 −/− mice ( Fig. 1e) , which is consistent with previous studies using IDO1 inhibitors 25, 26 . To test the role of the host immune system versus tumor-cell intrinsic effects 27 in the therapeutic function of PEG-KYNase, we used immunodeficient NOD-Scid Il2rg −/− (NSG) and Rag1 −/− mice. The NSG mice lack functional lymphocytes and are defective in innate immune function, whereas the Rag1 −/− mice lack only adaptive immunity. In both mouse strains, enzyme treatment had no effect on the growth of B16-F10 tumors ( Fig. 1f and Supplementary Fig. 9a ). More specifically, depletion of CD8 + cells abrogated the antitumor effect of enzyme treatment ( Fig. 1g) , which resulted in a median survival (21 d) similar to that of nature biotechnology advance online publication l e t t e r s the untreated mice (23 d) in Figure 1c . Furthermore, Kyn treatment had no direct effect on the growth of tumor cells in vitro ( Supplementary  Fig. 9b ). Collectively, these results indicated that the action of KYNase was dependent on the presence of CD8 + cytotoxic T cells. Following the treatment of C57BL/6 mice bearing large B16-F10 tumors (>100 mm 3 , day 10), we observed increased infiltration of CD8 + cells ( Fig. 2a) . One defining feature of an effective antitumor immune response is the presence of infiltrating effector CD8 + T cells into the interior of the tumor, as opposed to that in the margin 28 . Further examination by immunofluorescence microscopy revealed that in control tumors, CD8 + T cells were localized predominantly at the tumor margins ( Fig. 2b and Supplementary Fig. 10 ). However, the ratio of CD8 + T cells in the interior versus the margin of the tumor increased twofold in tumors from PEG-KYNase-treated animals (0.39 for control and 0.79 for the enzyme-treated group) ( Fig.  2b and Supplementary Fig. 10 ). We also observed a twofold increase in CD8 + tumor-infiltrating lymphocytes (TILs) that expressed the proliferation marker Ki67 (Fig. 2c) .
T cell polyfunctionality reflects a high degree of activation in the TME and correlates with protective antitumor responses in animal models and, notably, with favorable clinical outcomes in patients 29 . We observed that enzyme treatment resulted in an increased fraction (twofold) of CD8 + TILs that expressed granzyme B and were capable of producing IFN-γ, tumor necrosis factor (TNF)-α or interleukin (IL)-2 ( Fig. 2d,e and Supplementary Fig. 11 ). We also observed a smaller increase in CD4 + TILs that were capable of producing both IFN-γ and TNF-α ( Supplementary Fig. 12 ; P = 0.04). We did not observe any change in the proportion or proliferation status (Ki67 + cells) of CD4 + Foxp3 + T reg cells in tumors from treated animals ( Supplementary Fig. 12 ) and only a small effect on MDSCs, which did not reach statistical significance (Supplementary Fig. 13 ). Similar to these findings, no changes in the frequency of tumor-infiltrating CD4 + Foxp3 + T reg cells were observed after treatment with IDO1 inhibitors in multiple tumor models 14, 30, 31 . PEG-KYNase treatment resulted in a slight decrease in the percentage of T cells in the tumor draining lymph nodes (TdLNs) but no change in T cell activation or in the frequency of CD4 + Foxp3 + T cells, CD8 + T cells or MDSCs was observed ( Supplementary Fig. 14) . Likewise, IDO1 inhibitors have been shown to exert minimal effects on T cell activation in peripheral organs 12, 14, 30 . Collectively, our results demonstrated that PEG-KYNase affected CD8 + T cells in the tumor but not in the periphery.
Earlier studies have documented that small molecules that inhibit or otherwise modulate the immunosuppressive effects associated with IDO1 expression (e.g., indoximod) synergize well with anti-PD-1 checkpoint inhibition therapy in mouse models of melanoma and glioblastoma 14, 30 . Combination treatment of mice bearing large (~125 mm 3 ) B6-F10 tumors with both anti-PD-1 and PEG-KYNase (anti-PD-1+PEG-KYNase) resulted in 45% complete responses as compared to the ~10% responses observed in the group treated with anti-PD-1 alone ( Fig. 3a) . Neither CD8 + nor CD4 + TILs in PEG-KYNase-treated animals showed statistically significant differences in PD-1 expression, indicating that depletion of Kyn in the TME did not affect T cell PD-1 status (Supplementary Fig. 15 ). To determine the durability of the therapeutic response and the induction of immunological memory, we re-challenged the surviving mice 2 months after anti-PD-1+PEG-KYNase therapy cessation with B16-F10 tumor cells in the opposite flank. We found that 100% of the mice that showed long-term survival rejected the tumor (Supplementary Fig. 16a ).
We next examined the effect of combination therapy using antibodies to immune checkpoint proteins together with PEG-KYNase in mice that bore tumors expressing IDO1. In mice with CT26 tumors, anti-PD-1+PEG-KYNase treatment resulted in complete tumor rejection and immunity to re-challenge with CT26 tumor cells in 50% of the mice (Supplementary Figs. 6b and 7) . The 4T1 model of breast carcinoma is relevant to human breast cancer owing to its poor immunogenicity, its aggressiveness and its propensity for metastasis. 4T1 tumor cells express high levels of IDO1 and form very aggressive tumors 27 . Consistent with previous reports 32 , mice that bore large 4T1 tumors and that were treated with anti-CTLA4 showed a transient decrease in tumor growth but no overall survival benefit. In contrast, treatment with PEG-KYNase in combination with anti-CTLA4 showed a ~45% increase in median survival, as compared to that with treatment using anti-CTLA4 and deactivated enzyme, with 8% of the mice completely rejecting the tumors and becoming immune to re-challenge ( Fig. 3b and Supplementary Fig. 16b ). Finally, we evaluated whether PEG-KYNase could be combined with a clinically relevant cancer vaccine. The ImPACT vaccine platform comprises engineered tumor cell lines that express the heat-shock chaperone protein gp96 fused to an IgG-Fc domain. The gp96-Ig binds to endogenous tumor antigens and is secreted to the extracellular space to effectively stimulate cross-presentation, which elicits potent CD8 + T cell responses 33 . Mice bearing CT26 tumors received mitomycin-treated ImPACT CT26 vaccine cells together with inactive enzyme, PEG-KYNase alone or a combination therapy with ImPACT CT26 vaccine cells + PEG-KYNase as shown in Figure 3c . Treatment with either ImPACT cells+inactive enzyme or PEG-KYNase alone had a comparable effect on mean survival relative to that observed after treatment with vehicle, whereas the combination resulted in 60% tumor-free survival.
We used KYNase administration to selectively degrade Kyn in a manner that did not affect Trp catabolism and provided strong mechanistic evidence, by using multiple tumor types, that accumulation of Kyn in the TME is critical for immunosuppression by the Trp catabolism pathway. This conclusion is consistent with recent meta-analyses 4-7 and with experimental data reported by Sonner and co-workers showing that deletion of Gcn2, whose gene product had been proposed to be activated by IDO1-mediated depletion of Trp in the TME 3 , does not affect antitumor T cell responses in the B16 mouse model of melanoma 5 .
Of note, our data also demonstrated that pharmacologically optimized PEG-KYNase is a promising immunotherapeutic approach for cancer therapy. Multiple small-molecule inhibitors of IDO1 are undergoing clinical evaluation, and inhibitors of both IDO1 and TDO (dual inhibitors) were reported several years ago but are not yet in clinical development 1 . The most advanced IDO1 inhibitor, epacadostat, has shown promising efficacy in phase 2 clinical studies in combination with immune-oncology drugs 2 . However, a very recent (ECHO301) phase 3 clinical trial in melanoma failed to show improved efficacy relative to that with anti-PD1 treatment alone. KYNase offers several distinct pharmacological advantages over small-molecule inhibitors. First, unlike the small-molecule inhibitors of IDO1 currently in the clinic, PEG-KYNase eliminates Kyn from the TME irrespective of its source, i.e., regardless of whether it is produced by IDO1, TDO or by tumors that express both enzymes (Supplementary Fig. 17 ). Although dual inhibitors of IDO1 and TDO are in preclinical development, the complete blockade of Trp catabolism is likely to have a series of undesired side effects, including among others: (i) substantially elevated concentrations of Trp, which in turn can be carcinogenic 34 and can also have neurological effects due to the ensuing increase in the serotonin synthesis flux 20, 21 and (ii) the blocking of the synthesis of downstream metabolites of Kyn, including neuroprotective compounds such as kynurenic acid, and also the production of NAD and niacin, especially in the liver, which constitutively expresses TDO and plays a dominant role in Trp catabolism.
Second, PEG-KYNase eliminates Kyn completely and for prolonged periods (Fig. 1d) . The complete depletion of the extracellular Kyn pool-in contrast to the effect of IDO1 inhibitors, which only partially reduce systemic levels of Kyn (as they do not impact the constitutive flux originating from the TDO pathway)-could lead to the elimination of spontaneous Kyn byproducts that were recently shown to be potent AHR agonists 18 . The more favorable pharmacokinetics of PEG-KYNase ( Supplementary Fig. 5 ) may be advance online publication nature biotechnology l e t t e r s particularly advantageous for combination therapy with intravenously administered immune-checkpoint antibodies. Along these lines, we observed that administration of PEG-KYNase exhibited a comparable or stronger antitumor effect than clinical-stage small-molecule inhibitors of IDO1, most notably in combination therapy with anti-PD-1 (Supplementary Fig. 18 ).
Third, most of the IDO1 inhibitors under clinical investigation (and also published preclinical TDO inhibitors) structurally resemble Trp and have various degrees of AHR agonistic activity at physiologically relevant concentrations 35 . Thus, unlike PEG-KYNase, which disrupts the Trp catabolism-AHR axis by virtue of its ability to degrade extracellular Kyn, small-molecule inhibitors of IDO1/TDO can result in drug-induced, low-level AHR activation, a process that could induce certain immunosuppressive phenotypes 3, 16, 36 .
Fourth, although experience with tyrosine kinase inhibitors suggests that the use of small-molecule inhibitors of enzymes important for cancer growth frequently results in the acquisition of mutations that enable drug resistance 37 , such mechanisms are clearly not relevant for PEG-KYNase, whose function is to degrade an immunosuppressive metabolite. Finally, we note that we observed no evidence of toxicity or overt signs of autoimmunity, such as weight loss, organ size or vitiligo, with PEG-KYNase as a monotherapy or with the combination therapy regimens tested.
Because the bacterial enzymes used here to demonstrate the therapeutic effect of KYNase administration could pose an immunogenicity risk, we are engineering a human enzyme with the requisite Kyn degradation kinetics and high stability in vivo for optimal pharmacodynamic properties as desired for clinical development. Although the possibility that abrogation of the suppressive effects of the IDO pathway by PEG-KYNase could stimulate the elicitation of drug-specific antibodies (ADAs) in humans 38 , the use of a therapeutic agent comprising a human enzyme that is heavily PEGylated and thus shielded from immune recognition is expected to minimize immunogenicity concerns. Kyn, and especially its downstream products, have been established to have a plethora of both neurotoxic and neuroprotective effects (e.g., kynureninic acid) 21 . Numerous studies have suggested that an increased Kyn/Trp ratio in serum is associated with various neuropathologies and that, conversely, a reduction in circulating Kyn levels could be beneficial for mental health 21 . Nonetheless, given the complex roles of the Kyn pathway in neurophysiology, the consequences of depleting peripheral Kyn levels in the brain following enzyme therapy will need to be evaluated.
METHODs
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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We are grateful to N. Ashoura for assistance with various aspects of this work, data interpretation and comments on the manuscript. This work was supported by funding from NIH 1 RO1 CA189623 (E. Stone Preparation of PEGylated enzyme for mouse studies. Pf-KYNase and Mp-KYNase were expressed from 8-liter cultures that were grown and induced as described above. Cells were pelleted by centrifugation and then resuspended in 800 ml of buffer containing 50 mM sodium phosphate pH 8.0, 1 mM PLP, 300 mM NaCl, 1 mM PMSF, 25 mM imidazole, 0.1% Tween 20 and 25 U/ml Universal Nuclease. Resuspended cells were lysed by performing three sequential passes through a Nano DeBee homogenizer (B.E.E. International, Inc.) at 30,000 p.s.i. Solids were removed from the lysed cells by centrifugation at 20,000g for 30 min at 4 °C, and the lysate was passed through at 5-µm filter.
To ensure low endotoxin levels, glass columns that were pre-cleaned with 1 M NaOH were used for column preparations in all of the purifications. 17 mL Ni-NTA resin was pre-equilibrated with buffer containing 50 mM sodium phosphate pH 8.0, 0.1 mM PLP, 300 mM NaCl, 1 mM PMSF, 25 mM imidazole, 0.1% Tween 20 and 25 U/ml Universal Nuclease in a cold room at 4 °C. Filtered lysate was then passed over the pre-equilibrated column with a peristaltic pump at a flow rate of 3 ml/min. The resin was then washed with 5 CVs of buffer containing 50 mM sodium phosphate pH 8.0, 0.1 mM PLP, 300 mM NaCl and 25 mM imidazole, followed by 2.5 liter of endotoxin-free GIBCO PBS pH 7.4 (DPBS,Thermo Fisher) with 0.1% TritonX-114 (Sigma) + 0.1 mM PLP at a flow rate of 5 ml/min, and subsequently with 70 ml of endotoxin-free PBS. Enzymes were eluted with 200 ml of filtered (0.22 µm) elution buffer containing 100 mM sodium phosphate, pH 8.0, 300 mM NaCl and 300 mM imidazole, and PLP was added to a concentration of 1 mM. After incubation at 37 °C for 1 h, enzymes were subjected to buffer exchange with 100 mM sodium phosphate pH 8.5 using a Pall Corporation Minimate Tangential Flow Filtration dia-filtration system (10K capsule), and they were then concentrated to 5 mg/liter by centrifugation at 4,000g at 4 °C in Vivaspin Turbo 15 10,000 molecular-weight-cut-off (MWCO) ultrafiltration units (Sartorius, Goettingen, Germany). PLP was added to a concentration of 1 mM, and enzymes were incubated at room temperature for 30 min. Enzymes were then PEGylated by using a 100-fold molar excess of methoxy-PEG-CO(CH 2 ) 2 COO-NHS, 5,000 Da (NOF America Corporation) powder, which was added directly to the concentrated enzyme solution and stirred slowly for 0.5-1.0 h at room temperature. Then dia-filtration with a 30K capsule was used to remove excess methoxy-PEG-CO(CH 2 ) 2 COO-NHS and to perform buffer exchange into endotoxin-free DPBS. The PEG-KYNase protein was further concentrated by centrifugation at 4,000g at 4 °C in Vivaspin Turbo 15 10,000 MWCO ultrafiltration units. Glycerol was added to the concentrated enzyme such that the final concentrations of PEGylated enzyme and glycerol were 10 mg/ml and 15% vol/vol, respectively. PEG-KYNase was then sterile-filtered (0.22 µm) and flash-frozen in liquid nitrogen and stored at -80 °C. After at least 24 h, a small portion of enzyme was thawed and analyzed for catalytic activity. Endotoxin levels were determined using the Limulus amebocyte lysate (LAL) Chromogenic Endotoxin Quantitation Kit (Pierce). Purity and extent of PEGylation were determined by both SDS-PAGE on a 4-20% gradient gel and size-exclusion chromatography (SEC). The latter was performed on an Amersham-Pharmacia P-900 FPLC fitted with a sephadex S-200 10/300 column (GE Healthcare). Samples were run in PBS at an initial concentration of 1 mg/ml with an injection volume of 1 ml. MS analysis was carried out on a Thermo Scientific (Thermo Fisher Sci., Bremen, Germany, EU) Q Exactive benchtop Orbitrap detector loading an electrospray (ESI) source simultaneously operating in fast negative-positive polarity switching-ionization mode. The detector was run in full-scan MS analysis mode under the following conditions: spray voltage, 4.0 kV; capillary temperature, 300 °C; sheath gas, 55 (arbitrary units); auxiliary gas, 30 (arbitrary units); microscans, 1; AGC target, 1 × 10 6 ; maximum injection time, 100 ms; mass resolution, 70,000; considered m/z range, 115-450. To ensure the accuracy of the MS analysis, the detector was calibrated through the commercial calibration solutions provided by the manufacturer, followed by a customized adjustment for small molecular masses. Thus, masses at m/z 87.00877 (pyruvic acid), 117.01624 (D2-fumaric acid), 149.06471 (D3-glutamic acid), 265.14790 (sodium dodecyl sulfate) and 514.288441 (sodium taurocholate) were used for the negative-ionization mode, whereas masses at m/z 74.09643 (n-butylamine), 138.06619 (caffeine fragment), 195.08765 (caffeine) and 524.26496 (Met-Arg-Phe-Ala pentapeptide, MRFA) adjusted the mass accuracy of the positiveionization mode. The MS detector was calibrated before the analysis of each batch of samples, keeping the mass tolerance below 3 p.p.m. during the time of this research. The LC-MS platform of analysis was controlled by a personal computer that had the software Xcalibur v. 2.2 SP1.48 (Thermo Scientific, San Jose, CA, USA). Detailed chromatographic and MS properties of the determined metabolites are summarized in Supplementary Table 2 .
Liquid chromatography-mass spectrometry (LC-MS) data analysis.
Raw LC-MS data was automatically processed by SIEVE v. 2.2.58 SP2 (Thermo Fisher Sci., San Jose, CA, USA) with the following settings: frame parameter adjustment, m/z range 115-450; frame time width, automatic; m/z width, 10 p.p.m.; considered running time, 15 min; intensity threshold, 10,000 minimum counts; minimum scans across the peak, 5; signal-to-noise background, 3; an in-house database listing all of the target metabolites of the Kyn pathway metabolism was loaded using 3 p.p.m. as mass tolerance to perform the positive assignments; max RT shift, 0.2 min; MaxCharge, 1; peak algorithm to peak extraction, PPD; peak integration algorithm, ICIS (previously optimized using Xcalibur and a real sample as reference); DBlookup method, FRAMEMZ. Absolute quantification was performed by using the spiked known amount of their respective deuterated counterparts through the formula:
where W x and A x are, respectively, the weight and the area under the peak corresponding to the identified metabolite; W is and A is are, respectively, the weight of added deuterated internal standard and the area under its corresponding peak; F x,is is the relative response factor of the metabolite against its respective deuterated counterpart (1, in all cases). Results were normalized with respect to the measured volume and weight of serum and tissue samples, respectively. In contrast, relative quantification was done through the signals from metabolites and the closest deuterated standard eluted according to the formula W x = A x /A is . Absolute quantification was carried out by spiking samples with an internal standards solution that contained an accurate weight of all of the deuterated standards mentioned above, with the exception of D2fumaric and D3-glutamic acids, which were first solubilized in a water and methanol solution (50:50) with 2% DMSO. To analyze tumor tissue concentrations of Trp catabolism metabolites, C57B6L/6j inbred mice were inoculated with 5 × 10 4 B16-F10 cells on the right flank. After the tumors reached 25-35mm 2 in size (~12 d after inoculation), mice were then treated with one dose of 20 mg/kg Pf-KYNase pt. Tumors were excised at the indicated time points, snap-frozen in liquid nitrogen and stored at -80 °C. Tissue aliquots were weighed and placed in 2-ml tissue homogenization tubes and mixed with beads. Then 0.5 ml of a chilled water:methanol (50:50) solution was added. Samples were homogenized in a Precellys-24 cryohomogenizer (Bertin Technologies, Saint Quentin en Yvelines, France) at -5 °C at 5,000 r.p.m. during two cycles of 20 s. Lysates were recovered and poured into glass vials containing 0.5 ml of chilled chloroform. Homogenization tubes were washed with an additional 0.5 ml of a chilled water:methanol (50:50) solution. Glass vials were stirred at 1,500 r.p.m. for 3 min, centrifuged at 5,000 r.p.m. for 20 min at 4 °C, and the methanolic supernatants were poured in microcentrifuge tubes to be finally desiccated until dehydrated in a Centrivap vacuum concentrator at 4 °C (Labconco, Kansas City, MO, USA). Samples were resuspended in 15 µl of the internal standards solution and 135 µl of ultrapure water. The resulting 150 µl solutions were filtered and stored at -80 °C until LC-MS analysis.To analyze serum concentrations of Trp catabolism metabolites, serum from the tumor-bearing mice described in the paragraph above was collected following a terminal bleed. Blood was allowed to clot at room temperature for 10 min, and then it was centrifuged at 500g for 5 min. The serum fraction was drawn off, centrifuged a second time at 1,000g for 5 min and then stored at -80 °C until use. 10 µl of samples were diluted with 15 µl of the internal standards solution (incorporating a weight range of 7.3-8.5 ng) and 125 µl of water. The resulting 150 µl was stirred and run through a Nanosep 3K ultracentrifugal filter (Pall Co. Port Washington, NY, USA) at 8,000 r.p.m. for 2 h at 4 °C to separate the serum from solids and proteins. The resulting filtrates were poured into the LC vials and stored at -80 °C until LC-MS analysis.
In vitro T cell and tumor cell line assays. Naive CD8 + lymphocytes were magnetically isolated from single-cell suspensions that were prepared from the spleens of tumor-free C57B6L/6j mice using the EasySep Mouse Naive CD8 + T Cell Isolation Kit (Stemcell Technologies). Enriched naive CD8 + T cells (2 × 10 5 ) were stimulated in U-bottom 96-well plates that were pre-coated with 2 µg/ml of anti-CD3 (17A2, Ebioscience) and anti-CD28 (37.51, Ebioscience), in the presence or absence of the indicated concentrations of Kyn, Mp-KYNase (1 µM) or vehicle control (10% DMSO in PBS). After being stimulated for 48 h, the cells were transferred to new wells and rested for 24 h. Cells were then analyzed for viability by annexin V (BioLegend) and propidium iodide (PI) (Enzo Life Sciences) staining. Proliferation was determined by CFSE dilution. Cells were cultured at 37 °C in complete RPMI medium composed of Roswell Park Memorial Institute 1640 medium (RPMI 1640) supplemented with 10% FBS, 1× non-essential amino acids, 55 µM β-mercaptoethanol, 2 mM GlutaMAX, 1× penicillin-streptomycin-glutamine (100 U/ml penicillin, 100 µg/ml streptomycin, 292 µg/ml glutamine) and 1 mM sodium pyruvate (all from GIBCO).
In vitro enzymatic activity on human cell lines. SKOV3 human ovary adenocarcinoma (IDO1 + ) and A172 human glioblastoma (TDO + ) cell lines were obtained from the American Type Culture Collection (ATCC) and cultured in McCoy's 5A medium (10% FBS) and Dulbecco's modified Eagle's medium (DMEM, 10% FBS) culture medium, respectively. Cell lines were incubated at 37 °C in 96-well plates with either the IDO1 inhibitor INCB024360 (Epacadostat, Selleck; at 2 µM for SKOV3 cells and 20 µM for A172 cells), the TDO inhibitor 680C91 (WuXi Apptec; at 20 µM for all cells) or Mp-KYNase (at 0.36 mg/ml for all cells). In addition, A172 cells were stimulated with recombinant human IFN-γ (100 ng/ml, Sigma) to induce IDO1 expression to determine the effects on KYNase, INCB024360 and 680C91 on Kyn levels produced from dual expression of IDO1-and TDO. After 48 h, cell supernatants were collected, snap-frozen in liquid nitrogen and stored at -80 °C. Kyn concentrations of the supernatant were then determined by LC/MS. McCoy's 5A medium, DMEM and FBS were all purchased from GIBCO.
Mouse experiments. C57BL/6J, BALB/cJ, Ido1 −/− , Rag1 −/− and NOD-Scid Il2rg −/− (NSG) mice were purchased from Jackson Laboratories (Bar Harbor, Maine, USA). All mice were maintained in pathogen-free, ventilated cages with irradiated food and autoclaved water at UT Austin or WuXi AppTec. Experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at UT Austin or WuXi AppTec. Mice were monitored daily and euthanized by CO 2 asphyxiation and cervical dislocation before any signs of distress.
Pharmacokinetic analysis of PEG-Pf-KYNase in vivo. BALB/cJ mice were treated intravenously with a single 20 mg/kg dose of PEG-KYNase and then euthanized 1, 2 or 3 d after treatment to collect samples for analysis, using a sandwich ELISA for detecting the concentrations of PEG-KYNase. Briefly, 96-well Maxisorp plates (Thermo Fisher) were coated at 4 °C overnight with 5 µg/ml of anti-PEG (Abcam, PEG-B-47, ab51257) suspended in PBS. After washing five times with PBS+0.05% Tween 20 (PBST), the plate was blocked with 1% milk in PBS (PBSM) for 1 h at room temperature and then washed with PBST. Serum that was diluted 1:100 in PBSM was added to the plate for 1 h at room temperature, and then the plate was washed with PBST. Subsequently, 100 µl (0.83 µg/ml) of horseradish peroxidase (HRP)-labeled anti-PEG (Abcam PEG-B-47, ab202640) that was diluted 600-fold in PBSM was added for 1 h at room temperature, followed by washing of the plate with PBST. Plates were developed by addition of 100 µl of 1-Step Ultra TMB-ELISA Substrate Solution (Thermo, 34028), incubation at room temperature for 15 min, addition of 100 µl of 0.3 M sulfonic acid and then measurement of the absorbance at 450 nm. A standard curve was generated from known concentrations of PEGylated KYNase and was used to convert absorbance to enzyme concentration.
Tumor cell culture and vaccine cell line preparation. Mouse B16-F10 melanoma (CRL-6475), 4T1 metastatic mammary carcinoma (CRL-2539) and CT26 colon carcinoma (CRL-2638) cell lines were purchased from the ATCC, cultured according to manufacturer's directions and tested for mycoplasma using the Universal Mycoplasma test kit (ATCC). For vaccination studies, CT26 mouse colon carcinoma cells used for transfection were maintained in Iscove's modified Dulbecco's medium (IMDM) supplemented with glutamine and 10% FBS. The CT26-gp96-Ig (ImPACT, Heat Biologics, North Carolina) cell line was generated by transfecting CT26 cells with a DNA plasmid expressing murine gp96-Ig using Effectene transfection reagents (Qiagen Hilden, Germany) according to manufacturer's directions. Transfectants were selected with G418, and a single-cell clone that secreted a high level of gp96-Ig was isolated by limiting dilution. Gp96-Ig levels were determined by ELISA. All cells were cultured at 37 °C with 5% CO 2 .
Tumor models and therapy. C57B6L/6j inbred males and females, aged 6-8 weeks, were inoculated with 5 × 10 4 B16-F10 cells in the right flank. BALB/c mice were inoculated with 5 × 10 4 of CT26 cells in the right flank or with 5 × 10 4 4T1 cells in the mammary fat pad. Mice were treated with peritumoral injections of PEG-KYNase (20 mg/kg) or deactivated PEG-KYNase (heatdeactivated for 10 min at 100 °C). For CD8 depletion studies, mice were treated with anti-CD8 (10 mg/kg, clone YTS 169.4, Bio X Cell) or isotype control (10 mg/kg, clone LTF-2, Bio X Cell) 1 d before antibody treatment, and then every seventh day (for a total of three doses) the mice were administered PEG-KYNase. Anti-CTLA4 (10 mg/kg, clone UC10-4F10-11, Bio X Cell) or anti-PD-1 (10 mg/kg, clone RMP1-14, Bio X Cell) was administered by intraperitoneal injections as indicated. Epacadostat was administered by oral lavage twice daily (100 mg/kg), and NLG919 was administered in the drinking water (3 mg/ml). Tumor size was tracked three times weekly for the duration of the experiment by using calipers. Mice were euthanized after tumor sizes reached 4,000 mm 3 .
For cancer vaccine efficacy studies, tumors were first established by injecting 5 × 10 5 CT26 cells into the right flank of BALB/c mice. Vaccination was performed by intraperitoneal injection of 1 × 10 6 CT26-Gp96-Ig cells (described above), which were pretreated with mitomycin C (10 µg/ml) at 37 °C in 5% CO 2 for 2-3 h, administered on days 4, 7 and 10. PEG-KYNase or deactivated enzyme was injected peritumorally one time on days 4 and 7 and two times on day 10.
Tumor immune infiltrate phenotyping. Mice with established tumors (~125 mm 3 ) were administered two peritumoral injections of PEG-Pf-KYNase 3 d apart and necropsied 24 h after the second dose. Tumors, spleens, tumor draining lymph nodes (TdLNs) and contralateral inguinal lymph nodes (iLNs) were processed to obtain single-cell suspensions by mechanical digestion and treatment with red blood cell lysis buffer (BioLegend). Cells were then strained though a 40-µm filter and stained with fluorescently labeled antibodies to the following surface proteins: CD3-ε (clone 145-2C11; BD Biosciences), TCR-β (clone H57-597; Tonbo Biosciences), CD5 (clone 53-7.3; ThermoFisher), CD45.2 (clone 104 BioLegend), CD8 (clone 53-6.7 BioLegend), CD4 (clone GK1.5; BioXCell), CD25 (clone PC61.5; Tonbo Biosciences), PD-1 (clone 29.F1A12 BioLegend), Gr1 (clone RB6-8C5; Tonbo Biosciences), CD11b (clone M1/70; Tonbo Biosciences) and CD62L (clone MEL-14; Tonbo Biosciences). For all intracellular protein analysis, cells were co-incubated with a fixable viability dye (Tonbo Biosciences) during surface staining, and they were then fixed and permeabilized by using either Foxp3 Staining Buffer (Ebioscience) or BD Cytofix/Cytoperm kit, according to the manufacturers' instructions. Permeabilized cells were then incubated with fluorescently labeled antibodies to Ki67 (SolA15), granzyme B (GB11) or Foxp3 (FJK-16s).
To determine cytokine production, 1 × 10 7 cells from tumor digests were cultured in 1 ml of complete RPMI medium and stimulated at 37 °C with phorbol myristate acetate (PMA) and ionomycin (Ebioscience) in 48-well plates for 1 h, at which point brefeldin A (Ebioscience) was added. Cells were stimulated for an additional 4 h. After stimulation, cells were surface-stained with fluorescently labeled antibodies and viability dye, and then they were permeabilized by using the BD Cytofix/Cytoperm kit. Intracellular cytokine production was determined by using fluorescently labeled antibodies to TNF-α (TN3-19.12; EBioscience), IFN-γ (XMG1.2; Tonbo Biosciences) and IL-2 (JES6-5H4; BioLegend). All stains were done in flow cytometry wash buffer (PBS containing 1% FBS and 0.5 mM EDTA) at 4 °C for 30 min. An LSRFortessa instrument (BD Biosciences) was used for flow cytometric data acquisition, and data were analyzed with FlowJo (Treestar).
Immunostaining and microscopy.
Immunostaining of B16-F10 tumors was performed on 7-µm acetone-fixed cryosections according to standard protocols. The tissues were incubated with fluorophore-conjugated anti-CD3 (clone 17A2; Tonbo Biosciences) and anti-CD8 (clone 53-6.7; BioLegend) at 4 °C followed by counterstaining for nuclei with DAPI. Images were acquired using an Axio Imager A1 microscope (Zeiss,), with an AxioCam MRm camera (Zeiss), Zeiss EC Plan-Apochromat 10×/0.45 and Plan-Apochromat 20×/0.8 objectives with AxioVision 4.8 software (Zeiss). Adobe Photoshop v12.0 (Adobe) was used for overlays of the images from the different fluorescence channels and to adjust exposure uniformly across the images. For quantification, ten random, non-overlapping regions along the margin and interior were imaged for each tumor. The number of CD3 + CD8 + nucleated cells was then counted for each image. Sections that were stained with DAPI only were used as controls, and the treatment group that each tumor belonged to was unknown at the time to the individual doing the imaging and counting.
Statistical analysis. Statistical significance (P value) was determined by an unpaired Student's t-test (two-tailed) or the log-rank (Mantel-Cox) test. Significant P values are denoted by *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. All statistical analyses were performed using GraphPad Prism software (GraphPad). The sample size to achieve statistical significance was not calculated before the studies as the efficacy of the enzyme in the different tumor models was unknown prior. It was reasoned that 5-10 mice per treatment group in individual experiments would be indicate therapeutic efficacy.
Life Sciences Reporting Summary. Further information on experimental design and reagents is available in the

Data exclusions
Describe any data exclusions.
No data or replicates were excluded
Replication
Describe whether the experimental findings were reliably reproduced.
All experimental findings were reliably reproduced.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
The tumors of all mice are measured and volume is calculated. Mice re then partitioned so that the mean volume does not deviate between groups at the start of treatment.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
For quantitation of immunofluorescent images,the treatment group that each tumor belonged to was unknown at the time to the individual doing the imaging and counting.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance. 10 . Eukaryotic cell lines a. State the source of each eukaryotic cell line used. The CT26-gp96-Ig (ImPACT, Heat Biologics, North Carolina) cell line was generated by transfecting CT26 cells with a DNA plasmid expressing murine gp96-Ig using Effectene transfection reagents (Qiagen Hilden, Germany) according to manufacturer's directions. Transfectants were selected with G418 and a single cell clone secreting a high-level of gp96-Ig was isolated by limiting dilution. Gp96-Ig levels were determined by ELISA.
All other cell lines were purchased from ATCC b. Describe the method of cell line authentication used. none of the cell lines used have been authenticated c. Report whether the cell lines were tested for mycoplasma contamination.
The cells were tested for mycoplasma using the Universal Mycoplasma test kit from ATCC.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
no commonly misidentified cell lines were used
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
Male and female C57BL/6J, BALB/cJ, Ido1-/-, Rag1-/-and NOD-Scid IL2rγc-/-(NSG) mice 2-6 months of age were purchased from Jackson Laboratories (Bar Harbor, Maine, USA). All mice were maintained in pathogen-free, ventilated cages with irradiated food and autoclaved water at The University of Texas at Austin (UT Austin) or WuXi AppTec. Experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at UT Austin or WuXi AppTec. Mice were monitored daily and euthanized by CO2 asphyxiation and cervical dislocation prior to any signs of distress.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
the study did not involve human subjects cells were created by comparing TIL stimulated (PMA/Ion + BFA) to TIL incubated with BFA in the absence stimulation (PMA/ion) as shown in Supplementary Fig. 11 , along with activated splenic T-cells (PMA/Ion + BFA).
For in vitro viability assays, cells were gated by FSC vs SSC to include dying cells (FSC-lo/SSC-hi), while excluding debri. Gates to determine the percentage of viable cells were drawn as shown in Supplementary Fig. 3 .
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
